Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong’s Insilico Medicine, FT says
Publish Date: 2026-03-29 07:16:00
Source Domain: www.reuters.com
Here is a summary of the provided content in an unordered list:
- Partnership Announcement: U.S. drugmaker Eli Lilly is preparing to sign a significant $2 billion agreement with Hong Kong-based biotech company Insilico Medicine.
- Focus Area: The collaboration will involve leveraging Insilico Medicine’s artificial intelligence for drug discovery to develop and market a diabetes treatment.
- Exclusive Rights: Eli Lilly is set to acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine.
- Deal Structure: The agreement includes an upfront payment of $115 million and may reach over $2 billion if specific regulatory and sales milestones are met.
- Industry Trend: This deal highlights a growing trend among pharmaceutical companies to use AI in research and development to enhance efficiency and comply with FDA directives to reduce animal testing.
- Upcoming Announcement: The official deal announcement is anticipated later on Sunday.
- Unavailable Comments: Neither Eli Lilly nor Insilico Medicine have responded to immediate requests for comment from Reuters as of the report date.
If there are any specific questions on details not covered in this summary, please feel free to ask!
